Table 1.
Univariate and multivariate analyses of relapse-free survival according to clinical prognostic factors and immune infiltrates
| Univariate |
Multivariate |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| T stage 1–2 3–4 |
1 1.7 |
0.8–3.5 | 0.15 | 1 1.8 |
0.7–4.8 | 0.22 |
| N stage N0 N+ |
1 2.25 |
1.1–4.5 | 0.02 | 1 1.2 |
0.4–3 | 0.7 |
| Histological type Intestinal Diffuse |
1 1.15 |
0.5–2 | 0.9 | |||
| Neoadjuvant therapy Yes No |
1 1.8 |
0.8–3.6 | 0.08 | 1 0.5 |
0.3–1.1 | 0.06 |
| CD20 <median >median |
1 0.48 |
0.24–0.9 |
0.03 |
1 0.4 |
0.2–1 |
0.04 |
| TUMOR STROMA: | ||||||
| CD8 <median >median |
1 0.65 |
0.5–1.3 | 0.25 | |||
| Foxp3 <median >median |
1 2 |
1–4 | 0.04 | 1 1.6 |
0.7–3.5 |
0.1 |
| IL-17 <median >median |
1 1.15 |
0.5–2.3 | 0.7 | |||
| Tbet <median >median |
1 0.48 |
0.2–0.96 |
0.03 |
1 0.5 |
0.2–1.2 |
0.1 |
| INVASIVE MARGIN: | ||||||
| CD8 <median >median |
1 0.98 |
0.5–2 | 0.95 | |||
| Foxp3 <median >median |
1 1.23 |
0.6–2.5 | 0.5 | |||
| IL-17 <median >median |
1 0.88 |
0.45–1.8 | 0.7 | |||
| Tbet <median >median |
1 0.9 |
0.45–1.8 | 0.8 | |||